Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients
Makaleler > Tam Makale · 2007
Yazarlar: Senol Kobak, Fahrettin OKSEL, Yasemin KABASAKAL, EKER DOĞANAVŞARGİL
CLINICAL RHEUMATOLOGY, SCI Expanded İndekslerine Giren Dergi, Uluslararası, 2007, cilt 26, ss 2191-2194
DOI: 10.1007/s10067-007-0679-x
Özet
Secondary (AA) amyloidosis is one of the most significant complications of ankylosing spondylitis (AS) that frequently leads to proteinuria and renal dysfunction. Anti-tumor necrosis factor alpha (anti-TNF) agents are promising in inducing clinical remission by suppressing systemic inflammation in AA amyloidosis. We report three cases with AS-related AA amyloidosis that responded well to etanercept therapy. Despite treatment with disease modifying anti-rheumatic drugs, all three patients had active AS, marked proteinuria, impaired renal function, and low serum albumin level. During 1-year treatment with etanercept, all patients experienced gradual improvement in all of these parameters.